PRECISION BIOSCIENCES INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Precision BioSciences amended its consulting agreement with Dr. Stanley R. Frankel, MD, extending the contract term from June 30, 2026 to August 31, 2026. The amendment was executed June 29, 2026 by CEO Michael Amoroso and CFO Naresh Tanna on behalf of the company. No compensation amount, equity grants, or other material terms are disclosed in the filing excerpt.
Why this rating
Routine administrative contract extension with consultant; no financial detail disclosed; immaterial to $47M company unless compensation is substantial but undisclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.